Compare Intuit Inc. (INTU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Intuit Inc. trades at $309.59 (market cap $80.56B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Intuit Inc. is far larger — about 10.7× Spyre Therapeutics Inc. Common Stock's market cap, and Intuit Inc. pays a 1.83% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 67 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| INTU | SYRE | |
|---|---|---|
Market Cap | $80.56B | $7.52B |
Volume | 3,646,799 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $683.39 | $108.92 |
52-Week Low | $255.07 | $22.18 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $81.78B | $6.52B |
Dividend Yield | 1.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $305.99, up 1.07% with strong earnings momentum after beating Q4 2025 and Q1-Q2 2026 EPS estimates. The stock shows bullish technical signals with support at $302 and resistance at $312. Fundamentally, revenue grew to $18.83B in 2025 with a robust 21.29% net margin, while valuation ratios like P/E of 18.31 appear reasonable. Recent news highlights growth in QuickBooks monetization and AI initiatives, though class action lawsuits create near-term uncertainty.
Outlook remains positive with analyst consensus target of $379.68 (24% upside) and 60% buy ratings. Key opportunities include sustained revenue growth and margin expansion, while risks involve legal overhangs and competitive pressures in financial software. The stock offers attractive fundamentals but requires monitoring of lawsuit developments.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
